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Abstract
Background: Chronic insomnia is a prevalent disorder associated with significant psychosocial, health, and
economic impacts. Cognitive behavioral therapies (CBTs) and benzodiazepine receptor agonist (BzRA) medications
are the most widely supported therapeutic approaches for insomnia management. However, few investigations
have directly compared their relative and combined benefits, and even fewer have tested the benefits of sequential
treatment for those who do not respond to initial insomnia therapy. Moreover, insomnia treatment studies have
been limited by small, highly screened study samples, fixed-dose, and fixed-agent pharmacotherapy strategies that
do not represent usual clinical practices. This study will address these limitations.
Methods/design: This is a two-site randomized controlled trial, which will enroll 224 adults who meet the criteria
for a chronic insomnia disorder with or without comorbid psychiatric disorders. Prospective participants will
complete clinical assessments and polysomnography and then will be randomly assigned to first-stage therapy
involving either behavioral therapy (BT) or zolpidem. Treatment outcomes will be assessed after 6 weeks, and
treatment remitters will be followed for the next 12 months on maintenance therapy. Those not achieving
remission will be offered randomization to a second, 6-week treatment, again involving either pharmacotherapy
(zolpidem or trazodone) or psychological therapy (BT or cognitive therapy (CT)). All participants will be re-evaluated
12 weeks after the protocol initiation and at 3-, 6-, 9-, and 12-month follow-ups. Insomnia remission, defined
categorically as a score < 8 on the Insomnia Severity Index, a patient-reported outcome, will serve as the primary
endpoint for treatment comparisons. Secondary outcomes will include sleep parameters derived from daily sleep
diaries and from polysomnography, subjective measures of fatigue, mood, quality of life, and functional
impairments; and measures of adverse events; dropout rates; and treatment acceptability. Centrally trained
therapists will administer therapies according to manualized, albeit flexible, treatment algorithms.
Discussion: This clinical trial will provide new information about optimal treatment sequencing and will have direct
implication for the development of clinical guidelines for managing chronic insomnia with and without comorbid
psychiatric conditions.
Trial Registration: ClinicalTrials.gov Identifier: NCT01651442, Protocol version 4, 20 April 2011, registered 26 June 2012
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Background
Insomnia is characterized by difficulties initiating or
maintaining sleep and associated with significant distress
or impairments of daytime functioning that occur des-
pite adequate opportunities for sleep [1–4]. More than
33 % of adults experience insomnia at least intermittently,
whereas 10 % to 12 % suffer chronic sleep difficulties
[5–7]. Although its significance is often minimized, per-
sistent insomnia increases the risks for medical disor-
ders, accidents, alcohol/drug abuse, and psychiatric
illnesses [8–10]. When insomnia occurs co-morbid to a
psychiatric illness such as major depression, it compli-
cates disease management and often remains as a re-
sidual symptom that enhances risk for both suicide and
relapse [11–13]. Moreover, insomnia contributes to in-
creased healthcare utilization and costs [14]. More than
90 % of insomnia-related costs are attributable to work
absences and reduced productivity [15].
What are the treatment options?
Treatment options for insomnia include different classes
of medications, psychological/behavioral therapies, and a
variety of complementary and alternative therapies. The
most widely used pharmacological agents are allosteric
modulators of the GABAA receptor complex, often re-
ferred to as benzodiazepine receptor agonists (BzRAs).
These agents enhance the sleep-promoting effects of
homeostatic sleep-drive and decrease activity in arousal
systems (for example, acetylcholine, histamine, orexin/
hypocretin, and serotonin) [16]. BzRAs include several
benzodiazepines (for example, temazepam) and newer
non-benzodiazepine agents (for example, zolpidem). Add-
itionally, the melatonin receptor agonist, ramelteon; the
orexin receptor antagonist, suvorexant; and the tricyclic,
doxepin also have FDA approval for insomnia therapy. Fi-
nally, the use of antihistamines and the off-label use of sed-
ating antidepressants such as trazodone and amitriptyline
[17] are common for insomnia management. These agents
enhance sleep by diminishing arousal through blocking the
effects of wake-promoting systems [16].
Psychological/behavioral therapies target mechanisms
thought to perpetuate insomnia such as maladaptive sleep
habits, dysfunctional beliefs about sleep, excessive arousal,
and poor sleep hygiene practices [18, 19]. Included among
these approaches are various stand-alone strategies such as
stimulus control, sleep restriction, relaxation training, sleep
hygiene education, and cognitive therapy. Multicompo-
nent, cognitive behavioral therapies (CBTs) that combine
several of these therapeutic components to optimize out-
comes have become the most frequently used approaches.
How effective are the available insomnia therapies?
Of the various medications used for insomnia treatment,
FDA-approved BzRAs have the most efficacy and safety
data. Several meta-analyses, systematic reviews, and con-
sensus statements have summarized the efficacy of drug
therapies for insomnia [20–22]. For example, one meta-
analysis [21] examined 22 placebo-controlled trials involv-
ing benzodiazepines and zolpidem in primary insomnia
(PI) patients. This meta-analysis showed these agents
produce reliable short-term (median treatment dur-
ation = 7 days; range = 4 to 35 days) improvements of
sleep-onset latency (mean effect size = 0.56), number of
awakenings (effect size = 0.65), total sleep time (effect
size = 0.71), and sleep quality (effect size = 0.62). A few
long-term trials [23–25] have shown that BzRAs such as
zolpidem and eszopiclone have continued efficacy and
safety for periods of 3 to 12 months of nightly use. Most
treatment studies have focused on primary insomnia,
that is, insomnia not due to another medical, psychi-
atric, or sleep disorder. Whereas studies of BzRAs with
insomnia occurring comorbid to a mental disorder have
been limited, some data have shown that combining a
BzRA with antidepressant medications (SSRIs) is more
efficacious than SSRIs alone for treating both insomnia
and depression in patients with major depressive dis-
order [26–28]. In addition, trazodone is used widely
“off-label” for insomnia treatment [17] and some data
support its efficacy for treating insomnia occurring
comorbidly with major depression [29–33].
Psychological and behavioral therapies for insomnia
are also well supported by the scientific evidence. Meta-
analyses and systematic reviews [22, 27, 34, 35] indicate
that such treatments produce moderate to large im-
provements in sleep onset latency (effect sizes = .87 to
.88), total sleep time (effect sizes = 0.42 to 0.49), number
of awakenings (effect sizes = 0.53 to 0.63), duration of
awakenings (effect size = 0.65), and sleep quality ratings
(effect size = 0.94). Approximately 70 % to 80 % of pa-
tients benefit from treatment, with the best outcomes
resulting from multifaceted therapies such as cognitive
behavioral therapy (CBT) [19, 35]. Most of the evidence
is derived from studies of patients with primary insom-
nia. Applications of these therapies to patients with in-
somnia and comorbid psychiatric or medical disorders
have been more limited, but the available data suggest
these treatments produce sleep improvements among
patients with chronic pain [36], breast cancer [37], fibro-
myalgia [38], mixed medical disorders [39], and depres-
sion [40, 41]. These therapies also lead to improvements
in mood status and reductions in other disease-specific
symptoms [37, 38, 40].
What should be our first stage therapy, and what should
we do when that fails?
Deciding whether to use pharmacological or psycho-
logical/behavioral therapy is difficult because both forms
of treatment have their advantages and limitations [42,
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43]. Medications usually produce rapid improvements,
are widely available, and generally well tolerated, but ad-
verse effects (for example, daytime sedation) and a risk
of tolerance and dependence may complicate their use.
Furthermore, no data document the enduring benefits of
these agents after their discontinuation. In contrast, psy-
chological/behavioral therapy has minimal side effects, is
preferred by many patients, and results in enduring sleep
improvements long after termination of treatment
[43]. However, these therapies require more extensive
provider contact and have a slower therapeutic action
than medications. In addition, they are less widely
available than medications despite recent efforts to fa-
cilitate their implementation through abbreviated ther-
apy protocols [44], self-help interventions [45], and
Internet-based programs [46, 47].
Few head-to-head comparisons of medications and
psychological/ behavioral therapies [48–51] have been
made. In general, studies that compared BzRA therapy,
CBT, and combined BzRA/CBT therapy showed little dif-
ference in short-term outcomes, but superior longer-term
outcomes with CBT, compared to BzRA and combined
treatment. In contrast, a sequential treatment strategy that
commenced with 6 weeks of combined CBT/BzRA ther-
apy followed by an extended 6 months of CBT alone
proved superior to the continued long-term combined
therapy or CBT provided in the absence of any medication
[52]. Although informative, these studies are limited by
their small sample sizes, use of fixed-dose/fixed-agent
pharmacotherapy strategies that do not represent standard
clinical practice, and their predominant focus on patients
with primary insomnia. Hence, these findings provide lim-
ited guidance for decisions concerning the optimal first-
stage insomnia therapy and for the more challenging sub-
group of patients with comorbid psychiatric illnesses.
Some evidence suggests that patients with comorbidities
have more difficulties complying with behavioral interven-
tions [40], and they may not respond as well to treatment,
regardless of its specific modality, as do patients with pri-
mary patients [53]. In addition, a large proportion of pa-
tients fail to remit with first-stage therapy and retain
residual insomnia symptoms. In such situations, switching
from one therapy to another, on a trial and error basis, is
common clinical practice. However, no studies have exam-
ined which first-stage treatment is optimal for both pri-
mary and comorbid insomnias and which second-stage
treatment offers the best “added value” for patients who
do not remit following psychological or medication first-
stage therapy.
Objectives
The main objectives of this study are to compare short-
and long-term outcomes of psychological (behavioral
and cognitive) and pharmacological therapies (zolpidem
and trazodone) used sequentially for insomnia among
patients with and without comorbid psychiatric disor-
ders. Specifically, the study will compare the efficacy of
Behavior Therapy (BT) and zolpidem (ZOL) as first-
stage therapies and examine the moderating effect of
psychiatric comorbidity on outcomes. For those who do
not remit with the first-stage therapy, we will evaluate
the added value of Cognitive Therapy (CT) and trazo-
done (TRA) as second-stage therapy.
Methods
Study design and setting
The study is a randomized controlled trial with two
treatment stages and two treatment modalities (psycho-
logical therapy – behavior therapy and cognitive therapy;
medication – zolpidem and trazodone) for each stage
(see Fig. 1 for study design flow chart). Participants
meeting criteria (N = 224) are randomly assigned in a 1:1
ratio to zolpidem therapy (ZOL; n = 112) or behavioral
therapy (BT; n = 112), stratified by gender, age (<55 years
versus ≥ 55 years), and presence or absence of a comor-
bid psychiatric disorder. Randomization is based on a
computer-generated list of numbers for each site and
the participants’ allocation is concealed by using sequen-
tially numbered sealed-envelopes that are opened by study
coordinators only after a patient meets all selection cri-
teria and is ready to initiate treatment. Patients will be
randomly assigned to first-stage treatment involving either
zolpidem or behavioral therapy (BT). After this initial 6-
week therapy, patients in remission will be followed for
the next 12 months on maintenance therapy while nonre-
mitters will be re-randomized to a second-stage treatment
involving pharmacotherapy (zolpidem or trazodone) or
psychological therapy (BT or cognitive therapy (CT)). All
participants will be re-evaluated after second-stage ther-
apy, and at 3-, 6-, 9-, and 12-month follow-ups. Insomnia
remission, defined as a score of less than 8 on the Insom-
nia Severity Index, will serve as the primary outcome. Key
secondary outcomes will include sleep variables from diary
and PSG measures; ratings of sleep quality and daytime
functions; adverse events; and treatment acceptability.
Two sites are involved in the recruitment of patients:
Université Laval, Québec City, Quebec, Canada, and the
National Jewish Health, Denver, Colorado, United States.
A third site, Duke University, is involved in analyzing
polysomnographic (PSG) data. The study protocol has
been approved by the ethics committees at the two main
sites: the Research Ethics Board, Institut universitaire en
santé mentale de Québec, Québec, Canada, and the In-
stitutional Review Board (IRB) of National Jewish
Health, Denver, Colorado, USA. All important protocol
modifications will be communicated to both local IRBs.
Study coordinators obtain written informed consent
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from all prospective participants at their first screening
visit.
Participants
A total of 224 adults (aged 21 and older) with chronic
insomnia are recruited from the community and from
outpatient medical and mental health clinics and
through media advertisements, flyers, and letters to pri-
mary care physicians and mental health clinicians. The
inclusion and exclusion criteria are presented in Table 1.
These criteria are broad enough to obtain results widely
generalizable to the insomnia patient population com-
monly seen in clinical practice, including those with pri-
mary insomnia and insomnia comorbid to a psychiatric
disorder. Individuals with a comorbid medical condition
are excluded only if the medical condition is life threat-
ening or would contraindicate the use of study
medications.
Individuals using sleep-promoting medications (pre-
scribed or over-the-counter) are included if they are will-
ing and able to discontinue medications at least 2 weeks
before the baseline assessment. Participants using alco-
hol as a sleep aid or alcohol after 7:00 pm on a regular
basis are required to discontinue this practice at least
2 weeks prior to the baseline assessment. Individuals
using psychotropic medications (for example, anxiolytics
and antidepressants) are not automatically excluded
from the study. Those on stable dosages (for at least
3 months) of SSRI or SNRI medications, and who show
at least partial remission from their mood or anxiety dis-
order, are accepted in the study if they meet the selec-
tion criteria above. Patients using TCAs, MAOIs, or
Fig. 1 Flow chart of study design
Table 1 Selection criteria
Inclusion criteria (combination of criteria from the Diagnostic and Statistical
Manual of Mental Disorders, 4th edition (DSM-IV), Insomnia Research Diagnostic
Criteria, and International Classification of Sleep Disorders, 2nd edition
▪ Males and females age ≥ 21 years
▪ Complaint of persistent (that is, > 1 month) difficulties initiating or
maintaining sleep despite adequate opportunity for sleep
▪ Sleep onset latency or wake time after sleep onset≥ 30 minutes for
three or more nights per week during 2 weeks of sleep diary monitoring
▪ Insomnia Severity Index (ISI) total score > 10, indicating at least “mild”
insomnia
▪ Score≥ 2 on either the interference or distress item of the screening
ISI, indicating the insomnia causes significant distress or impairment in
social, occupational, or other areas of functioning
Exclusion criteria
▪ Untreated psychiatric disorder (for example, major depression), as
these conditions have specific treatments and it would be
inappropriate not to offer those treatments
▪ Lifetime diagnosis of any psychotic or bipolar disorder, as sleep
restriction and medications for insomnia may precipitate mania and
hallucinations
▪ Imminent risk for suicide
▪ Alcohol or drug abuse within the past year
▪ Terminal or progressive physical illness (for example, cancer or COPD)
or neurological degenerative disease (for example, dementia)
▪ Current use of medications known to cause insomnia (for example, steroids)
▪ Sleep apnea (apnea/hypopnea index > 15), restless legs syndrome,
periodic limb movement during sleep (PLMS with arousal > 15 per
hour), or a circadian rhythm sleep disorder (for example, advanced sleep
phase syndrome)
▪ Personal or familial (first-degree relatives) history of sleepwalking
▪ Women being pregnant or expecting to become pregnant during
treatment
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atypical antidepressants are excluded even if in remis-
sion, as the effects of these medications on sleep might
confound interpretation of the findings.
Measures
Screening instruments
Structured clinical interviews are used to screen poten-
tial participants. The Insomnia Interview Schedule [54]
is an interview assessing the nature, severity, and fre-
quency of the current insomnia problem, as well as its
history, course, and contributing factors. The Duke
Structured Interview for Sleep Disorders [55] is used to
assist in ascertaining sleep disorder diagnosis according
to DSM-IV-TR [56] and International Classification of
Sleep Disorders criteria [3]. This instrument has accept-
able reliability and discriminant validity [57]. In addition,
the Structured Clinical Interview for DSM-IV Axis I Dis-
orders (SCID) [58] is used to classify enrollees as having
primary or comorbid insomnia and to identify study
candidates with disorders leading to exclusion. All inter-
views are audiotaped and reliability checks are con-
ducted on 15 % of them. The Folstein Mini-Mental State
Exam (MMSE) [59] is administered to exclude partici-
pants with cognitive deficits (MMSE score < 27) that
make them unable to give informed consent or fully par-
ticipate in an interactive treatment.
Sleep diary
Subjective estimates of sleep and wake times are ob-
tained daily using a web-based sleep diary. Participants
are instructed to report the following information about
their previous night’s sleep: bedtime, sleep onset latency,
number and length of nocturnal awakenings, time of
final waking, rising time, and subjective rating of sleep
quality. Additional questions query daytime napping,
and caffeine, alcohol, and sleep medication use. Partici-
pants with missing data are contacted by phone to re-
mind them to fill out the diary daily. Electronic sleep
diaries are obtained for 2 weeks at baseline and at each
subsequent assessment period, as well as for the entire
treatment period (first- and second-stage).
Polysomnography
Participants undergo ambulatory nocturnal polysomno-
graphic (PSG) monitoring at their home using their typ-
ical bedtimes and arising times for baseline/screening
(two nights) and outcome assessment (2 nights after
each treatment phase). PSG monitoring is conducted ac-
cording to standard procedures with regard to montage
and sampling rate (256 Hz) and records are scored, blind
to treatment assignment, in 30-second epochs using stand-
ard criteria [60] for sleep staging and sleep-associated
events (for example, apneas). Scoring is done at the
Duke University Insomnia and Sleep Research Program
by trained technologists under the supervision of an ex-
perienced polysomnographer who is board-certified in
sleep medicine (AK).
Outcome measures
The primary study end point is the proportion of indi-
viduals achieving remission, using total scores from the
Insomnia Severity Index (ISI) [61, 62] completed during
the last treatment visit and at the following week (weeks
5 and 6 of each treatment stage). Remission is defined as
a mean ISI score < 8 for weeks 5 and 6, with neither one
of these two ISI score > 10. The ISI is a seven-item self-
report questionnaire that provides a global measure of
perceived insomnia severity based on several indicators
(for example, difficulty falling or staying asleep, satisfac-
tion with sleep, and degree of impairment with daytime
functioning). The total score ranges from 0 to 28: 0 to 7
(no clinical insomnia), 8 to 14 (subthreshold insomnia),
15 to 21 (insomnia of moderate severity), and 22 to 28
(severe insomnia). The ISI has been validated extensively
and has proven sensitive to therapeutic changes [52, 62].
Several secondary outcomes are also monitored in-
cluding sleep/wake variables: sleep onset latency (SOL),
wake time after sleep onset (WASO), total sleep time
(TST), sleep efficiency (SE) derived from both sleep diar-
ies and PSG. Participants also complete the Pittsburgh
Sleep Quality Index [63] and the Dysfunctional Beliefs
and Attitudes about Sleep scale [54] at each assessment
to examine changes in overall sleep quality and sleep-
related cognitions. A clinical global improvement rating
is completed by a blinded rater after each treatment.
This rater also interviews participants at the conclusion
of their study involvement to determine whether they
continue to meet diagnostic criteria for insomnia.
To examine treatment-related changes in daytime
functions, participants complete the Multidimensional
Fatigue Inventory (MFI) [64], the SF-36 Health Survey
(SF-36) [65], and Work and Social Adjustment Scale
(WSAS) [66]. The MFI is a 20-item scale [64] assessing
several dimensions of fatigue (for example, physical and
mental). The SF-36 is a quality-of-life measure that com-
prises eight scales and two summary measures (physical
health and mental health) [65]. The WSAS assesses the
functional impact of a specific disorder (in our study, in-
somnia) on five domains: ability to work, home manage-
ment, social leisure activities, private leisure activities,
and relationships. Changes in mood status are assessed
with the Beck Depression Inventory-II (BDI-II) [67] and
the Trait part of the State-Trait Anxiety Inventory
(STAI-Trait) [68].
Adverse events (AE) are monitored with the Systematic
Assessment for Treatment Emergent Events (SAFTEE),
a reliable and valid instrument for assessing AEs re-
lated to study treatments [69]. AEs are also monitored
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for patients treated with BT and CT because some
interventions (for example, sleep restriction) may
produce excessive daytime somnolence. Finally, we use
an amended version of the Therapy Evaluation Ques-
tionnaire to assess treatment credibility, acceptability,
and patient satisfaction [70].
Procedures
After an initial telephone screening for eligibility, study
candidates complete several paper-and-pencil screening
measures (see Table 2 for details). Then, they complete
PSG to rule out other sleep disorders (for example,
apnea and PLMS). In the absence of such disorders dur-
ing the first PSG screening night, a second consecutive
PSG is conducted for baseline assessment. After com-
pleting baseline assessment, patients meeting criteria are
randomized to one of the first-stage therapies. After
completing the initial 6-week treatment, remitters re-
main on maintenance therapy. Remitters from the zolpi-
dem condition attend a monthly follow-up visit with the
physician, who administers the SAFTEE and provides
medication supply for nightly use (if needed) until the
next visit. Remitters from the BT condition receive
monthly phone calls during which the SAFTEE is
administered, but there are no further therapy visits.
Nonremitters following first-stage treatment are encour-
aged to accept randomization to a second-stage treatment
provided over the next 6 weeks. Nonremitting participants
treated with BT initially are randomized either to another
psychological treatment, that is, cognitive therapy (CT), or
to a medication therapy (ZOL). Those treated with medi-
cation (ZOL) initially are tapered off their medication and
randomized to BT or to a different medication (trazodone,
TRA). During this second treatment, all participants con-
tinue to complete a nightly sleep diary, the ISI (weekly),
and other questionnaires (at week 12), whether they re-
ceive a second therapy or not. Measurements are taken at
baseline, at the end of first- and second-stage therapies
(that is, weeks 6 and 12), and at follow-ups conducted 3,
6, 9, and 12 months after the week 12 assessment.
Participants receiving second-stage therapy complete
two additional PSG nights at week 12. Subsequently, all
participants enter follow-up and are contacted monthly
for adverse event monitoring (that is, in-person visits
with the physician for participants receiving medication
in second-stage therapy; phone calls by the research co-
ordinator for participants in the BT and CT conditions).
For all participants, in-person visits occur 3, 6, 9 and
Table 2 Timing of clinical assessments and measures throughout the study
Instruments/time point Screen Baseline Tx-1 Post-1 Tx-2 Post-2 3-month FU 6-month FU 9-month FU 12-month FU
Medical history/physical exam X
Mini-Mental State X
Vital signs X X X X X X X
Insomnia Interview Schedule X X X X X X X
Duke Structured Interview for
Sleep Disorders
X X X X X X X
Structured Clinical Interview for
DSM-IV Disorders
X X X
Sleep diary X X X X X X X X X X
Polysomnography X a X a X X
Insomnia Severity Index X X X X X X X X X X
Clinical Global Improvement X X X X X X
Pittsburgh Sleep Quality Index X X X X X X X
Dysfunctional Beliefs and Attitudes
about Sleep Scale
X X X X X X X
Multidimensional Fatigue Inventory X X X X X X X
SF-36 Health Survey X X X X X X X
Work and Social Adjustment Scale X X X X X X X
Beck Depression Inventory X X X X X X X
State-Trait Anxiety Inventory X X X X X X X
Systematic Assessment for Treatment
Emergent Events
X X X X X X X X X
Treatment Evaluation Questionnaire X X X X X X
FU, follow-up; Tx-1, first-stage treatment 1; Tx-2, second-stage treatment
a Screening (full montage to rule out other sleep disorders) and baseline (sleep montage only) assessments are conducted on consecutive nights
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12 months after the end of the second-stage treatment,
when participants are interviewed with the Duke Sleep
Interview Schedule to determine if they meet criteria for
insomnia disorder. They are asked to complete additional
electronic sleep diaries (2 weeks), outcome questionnaires,
and the SAFTEE. SCID interviews serve to document psy-
chiatric diagnoses at the 6- and 12-month follow-ups.
Treatments
Psychological therapy
The first-stage psychological therapy consists of behav-
ioral therapy (BT), which includes sleep restriction [71]
and stimulus control procedures [72]. These well-
established strategies are designed to strengthen homeo-
static sleep drive, consolidate sleep via reducing time in
bed, establish a regular sleep schedule, and curtail sleep-
incompatible behaviors. Although full CBT may represent
the psychological treatment of choice, we have chosen to
employ only its core behavioral elements as first-stage
therapy because it is briefer, easier to deliver, and, ultim-
ately, more transferable to various clinical settings.
The second-stage psychological treatment consists of
cognitive therapy (CT). CT is aimed at altering sleep-dis-
ruptive and mood-disturbing cognitions that exacerbate
the vicious cycle of insomnia. Such cognitions are typically
related to thoughts and beliefs about unmet sleep require-
ments and potential insomnia consequences. Perpetuating
mechanisms such as excessive self-monitoring and worries
are also prime targets for CT. CT follows standard pro-
cedures to identify and alter these sleep-interfering
cognitions via recording automatic thoughts, Socratic
questioning, constructive worry, and behavioral experi-
ments [18, 73].
We chose CT as a second-stage therapy because it is
more time consuming, requires more training, and may
not be essential for all patients with insomnia. Yet, be-
cause of its unique features in targeting some critical
cognitive perpetuating mechanisms (for example, wor-
ries) shared by insomnia and some comorbid psychiatric
disorders (for example, anxiety, and depression) [74],
and not specifically addressed by BT, the addition of CT
as a second-stage therapy provides an opportunity to
evaluate its unique contribution to outcomes among pa-
tients with comorbid psychiatric disorders. This condi-
tion is also likely to make the switch within the
psychological treatment modality (that is, from BT to
CT) more equivalent conceptually to the switch within
the pharmacotherapy modality (that is, from zolpidem
to trazodone).
Medication
The first-stage pharmacological treatment involves zolpi-
dem (ZOL), sublingual, 5 to 10 mg, taken nightly at bed-
time. The choice of zolpidem as a first-stage therapy was
based on the extensive literature documenting its effi-
cacy for insomnia and on the fact that it is among the
most commonly prescribed medications for insomnia
[29, 33, 75]. It has also been shown efficacious for in-
somnia in depressed patients treated with antidepressant
medications [76]. All participants start with an initial
dose of 5 mg, which is titrated up to 10 mg based on
therapeutic response, side effects, and the patient’s age
and gender (based on FDA recommendations, dosage is
limited to 5 mg in women). Support and encouragement
to comply with the prescribed medication regimen is
provided by the prescribing physician, but no behavioral
or cognitive intervention is allowed during these consul-
tations visits. All medications are dispensed by the phar-
macy at each site.
The second-stage pharmacotherapy consists of trazo-
done (TRA; 50 to 150 mg), taken 30 minutes before bed-
time. We chose trazodone because it is also among the
most commonly prescribed medications for insomnia
(off-label) in clinical practice [29, 33]. It has a differ-
ent mechanism of action than BzRAs and has shown
efficacy for insomnia co-occurring with major de-
pression [30–32, 77].
At the end of the first-stage treatment, participants
who do not achieve remission on medication receive a
final drug supply and a written withdrawal schedule (de-
signed by the study physician). They are informed of
possible rebound insomnia and instructed not to discon-
tinue medication abruptly. Although the time required
to discontinue medication may vary across individuals, a
2- to 3-week taper schedule is adequate for most. Those
who achieve remission with medication provided as a
first-stage treatment, as well as those provided a medica-
tion for second-stage treatment, stay on medication
through follow-ups. Subsequently, these patients use
a similar discontinuation schedule at the end of the
12-month follow-up. Those who wish to continue
medication are referred to their primary care phys-
ician for further follow-ups.
Treatment implementation and monitoring
All four treatments are administered in the context of
four, individual, sessions led by clinical psychologists
(BT, CT) or physicians/physicians’ assistants (ZOL,
TRA) spread over a 6-week period. Consultation visits
take place at weeks 1, 2, 4, and 6 and last 50 minutes for
psychological treatments and 20 minutes for medication
treatments. In addition to the main content pertaining
to each treatment modality, both first-stage treatments
(BT and ZOL) include generic sleep hygiene education
about basic sleep hygiene education about the impact of
stimulants, alcohol, caffeine, and exercise on sleep. The
ISI and SAFTEE are administered at all consultation
visits of both treatment stages. Clinicians use treatment
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manuals and receive ongoing supervision during the
course of the study to standardize treatment administra-
tion. Therapy sessions are audiotaped and approximately
10 to 15 % of those sessions will be rated with a standard
checklist by blinded raters for the presence of essential
ingredients of a given treatment and for the absence of
proscribed treatment instructions. Participants’ compli-
ance with treatment protocols (for example, time spent
in bed and the use of medication) are monitored by
treating clinicians via sleep diaries and pill count. Treat-
ment is discontinued or modified if adverse events
are reported. During the trial, any treatment deemed
necessary for other medical or psychiatric conditions
is permitted.
Data management and analysis
Data management
All case record forms are anonymized to ensure confi-
dentiality. Electronic sleep diaries are used to foster ad-
herence with daily data monitoring and minimize data
collection errors. Data entry for other paper-and-pencil
measures is completed at each site in an Access database
by research assistants. A statistician revises data period-
ically to identify missing or incoherent data. Upon com-
pletion of the study, we will investigate missing data
patterns to ascertain if data are missing completely at
random, at random or not at random [78]. Our primary
analyses will use statistical models robust to the first two
data patterns, although we will perform sensitivity ana-
lyses for missing data not at random considering specific
reasons for attrition if needed [79]. No data imputation
will be performed, and all available observations will be
included in inferential analyses. Trial results will be
communicated through publications in peer-reviewed
journals, scientific conferences, and lay public conferences.
Primary outcome analyses
All primary outcome analyses will be conducted based
on the Intention-to-Treat principle. Accordingly, all pa-
tients with at least one set of post-baseline data will be
included in these analyses. To control for possible site
effects, the clinical site will be included as a main effect,
and the inclusion of a clinical site interaction with other
main effects (when appropriate) will be investigated for
significance.
Hypothesis 1a The proportion of patients achieving re-
mission with the first-stage therapy and sustain remis-
sion through follow-up will be higher among those
receiving BT than among those receiving zolpidem. A
standard logistic regression will be used to compare the
probability of short-term (after first-stage treatment)
and sustained remission (primary outcomes) between
BT and zolpidem conditions. Sustained remission is
defined as remission being achieved after first-stage
therapy and maintained at 12 weeks (and at the 12-
month follow-up).
Hypothesis 1b A lower proportion of CMI patients will
achieve remission with first-stage therapies than will
those with PI. A similar logistic regression will be used
to compare the probability of short-term (after first-
stage treatment) and sustained remission according to
the presence or absence of psychiatric comorbidity. This
effect will be investigated as a moderator of the impact
of first-stage treatment on remission. The significance of
a moderator is presumed by a significant moderator ×
treatment interaction. To investigate the moderating ef-
fect of psychiatric comorbidity, this variable and its
interaction with treatment will be added as fixed effects
to the model. A significant interaction will then be ex-
plored using simple effects to test if CMI is associated to
poorer acute and long-term outcomes for each first-
stage therapy.
Hypothesis 1c Secondary outcomes (sleep, fatigue, and
mood) will show greater improvements through treat-
ment and follow-up for those receiving BT than for
those receiving zolpidem. Group comparisons for sec-
ondary outcome measures will be performed using a
mixed model approach [80], including a generalized
mixed-effect regression models for binary variables (for
example, diagnosis for insomnia) and a normal mixed-
effect regression model for continuous variables. In both
modeling approaches, treatment, time, and potential
confounding factors will be included in the models as
fixed main effects. The models will also include random
effects for intercept and slope (patient by time) for each
subject.
Hypothesis 2a The insomnia remission rate after the
second-stage treatment for all conditions combined will
be 20 % higher than with first-stage treatment (that is,
increment from 40 % to 60 %). Since participation in the
second randomization is conditional upon not remitting
with first-stage therapies, generalized estimating equa-
tions models (GEE) will be used to test whether the
overall remission rate significantly increased.
Hypothesis 2b Of all patients who enter second-stage
treatment, a greater proportion who switches modalities
(from psychological to medication treatment, or vice-
versa) will achieve remission and sustain it through
follow-up than will those staying within a treatment mo-
dality. To maximize degrees of freedom, weighted GEE
models will be used to compare remission rates after
12 weeks of treatment and sustained remission after
12 months, according to two main effects: (a) having
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received BT or zolpidem during Stage I and, (b) having
switched treatment modality or not for second-stage
treatment. These main effects and their interactions will
capture the partial effect of each treatment combination
while accounting for relevant patient trajectory (data
from first- and second-stage therapies). Other main fixed
effects (for example, time) and potential baseline covari-
ates will be included. Weights will be computed for each
case after specifying a dropout model estimated from
the observed dropout patterns.
Hypothesis 2c CMI patients who enter second-stage
treatment will show a higher remission rate with treat-
ments that target sleep and mood symptoms (CT and
trazodone) than with treatments targeting primarily
sleep (BT and zolpidem). This added therapeutic effect
will be higher in CMI than in PI patients. Two tests will
be of primary interest within the full factorial (comor-
bidity × conditions × time) weighted GEE model: (a) an a
priori contrast to examine remission rates after second-
stage treatment according to whether CMI patients re-
ceived the “mood addressing” sequences (BT→CT or
ZOL→ TRA) or the “non-mood” sequences (BT→ ZOL
or ZOL→ BT), and (b) a comorbidity × treatment inter-
action will be used to compare whether the added thera-
peutic effect obtained by addressing mood symptoms is
higher for CMI than PI patients. Significant interactions
will be examined with simple effects to test whether
temporal changes observed for each subgroup during
second-stage therapies are significant. Other fixed effects
such as first-stage therapy and baseline covariates will be
included.
Hypothesis 2d Secondary outcomes will show response
patterns consistent with Hypotheses 2a through 2c.
When the outcomes are assessed on a binary scale, iden-
tical analyses will be performed. When the outcome are
assessed on a continuous scale, weighted GEE will be
specified with a normal distribution and an identified
link function.
Sample size and detectable effect size
All sensitivity power analyses were computed following
procedures outlined by Stroup [81] for mixed models
and Dahmen et al. [82] for weighted GEE models and
were based on a two-tailed 5 % alpha and 80 % power.
Based on studies conducted by our group [52, 83] and
on recent reviews [84], attrition rates of 10 % were used
as attrition estimates in the computation of detectable
differences.
Power computations for the hypotheses related to the
primary outcome (remission rate) are reported here
using the GEESIZE program [82]. For hypothesis 1a, our
expected sample size of 224 (n = 200 at post-1 after
attrition) will give a standard 80 % power to detect a dif-
ference of 17.7 % in sustained remission rates between
BT and zolpidem after stage-1 therapies. For hypothesis 2a,
the initial sample size of 224 (effective sample at Post 2 =
178 after taking into account attrition) will give a stand-
ard power to detect a increment of 9.9 % in remission
rates between Post I and Post II assessments (all condi-
tions confounded), assuming a working correlation of
0.70. For hypothesis 2b, the same sample after attrition,
excluding patients who are already remitted (effective
sample size = 90) will give a standard level of power to
detect a difference of 18.3 % in remission rates at Post II
between patients who switched treatments and those
who did not. If remitted patients are included to in-
crease power, sensitivity would also be increased, allow-
ing the detection of a difference of 13.3 % or larger in
remission rates between patients who switched treat-
ments and those who did not.
Discussion
This study addresses research priorities set forth in the
2005 NIH State-of-the-Science Conference on the
Manifestations and Management of Chronic Insomnia
in Adults. As noted in the summary statement from
that conference, “…little is known about the compara-
tive benefits of these treatments, their combination,
and their effects on understudied features of chronic in-
somnia. To address this lack of knowledge, randomized
controlled trials will be required that are large scale and
multi-site and compare at least two effective or promis-
ing treatments. This should include comparisons be-
tween pharmacological agents as well as between those
agents and CBT.” This dual-site trial is specifically de-
signed to address such objectives and to test the effi-
cacy of such treatments in patients with both primary
and comorbid forms of insomnia.
Currently, few data are available concerning the rela-
tive efficacy of the psychological/behavioral and BzRA
therapies for managing chronic insomnia disorder since
large multisite head-to-head comparisons of these treat-
ments have yet to be conducted. Furthermore, there are
virtually no data on how well each of these treatment
approaches performs in producing and sustaining in-
somnia remission over time. Finally, the value of se-
quenced treatments for patients who fail to achieve
insomnia remission when BT or BzRA are used as first-
stage therapies has yet to be investigated. The current
study was designed to address these gaps in the insom-
nia treatment literature. It has the following innovative
features: 1) enrollment of participants with chronic in-
somnia disorder, with and without psychiatric comorbid-
ity; 2) use of the clinically-relevant primary outcome,
insomnia remission; 3) use of a sequential treatment
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design that tests various first-stage-to-second-stage
treatment sequences; 4) flexible medication dosing, ra-
ther than a fixed-agent/fixed dose design; and 5) collec-
tion of AE data for both psychological and medication
therapies so that the relative safety of the two ap-
proaches can be examined.
Given the high prevalence, morbidity, and societal costs
of insomnia, this study is likely to yield new information
that will have direct implications for the clinical manage-
ment of insomnia, and as such, it will benefit both individ-
uals who suffer from insomnia and society in general. This
project should provide new and relevant information that
contributes to the development of clinical guidelines for
CMI and PI management, guidelines that are critically
lacking.
Trial status
The trial is currently in the active recruitment phase. As
of 30 December 2015, 185 participants of the required
224 have been enrolled.
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